Does A2M predicts cancer appearance or progression in skin? (ISSN 2753-8176 (online))
Does A2M predicts cancer appearance or progression in skin? (ISSN 2753-8176 (online))
1.Ana Pedro
1.Gwyntwr1386 Health & Social Care, Harold Tomlin Day Centre, 24 Grosvenor Street, Chester, CH1 2DD. info@gwyntwr1386.com
Introduction
1.Ana Pedro
1.Gwyntwr1386 Health & Social Care, Harold Tomlin Day Centre, 24 Grosvenor Street, Chester, CH1 2DD. info@gwyntwr1386.com
Introduction
1.Gwyntwr1386 Health & Social Care, Harold Tomlin Day Centre, 24 Grosvenor Street, Chester, CH1 2DD. info@gwyntwr1386.com
Introduction
Introduction
In our previous article we analyzed the hypothesis that A2M predicts cancer appearance or progression in the breast (1), now we analyse if this hypothesis might be true as well in the case of the skin.
The interstitial fluid and the deriving lymph are in direct contact with the cellular layer of each organ. Therefore, the analysis of the composition of the lymphatic fluid (LF) may provide precise pathological biochemical and cellular information about an organ including the skin (2). For these reasons, we collected LF samples both from healthy patients and cutaneous melanoma (CM) patients suffering from different stages of the disease, and submitted these samples to proteomic analysis and analyzed the expression of A2M in these samples (Table 1).
Results and Discussion
We found out (fig.1) that A2M score in control 2 is much bigger than in control 1 so might control 2 be prone to develop cancer? Also, when we analyze LF samples from melanoma with just lymph node (LN) metastasis (fig1.), we found out that sample 9 has a small A2M score (smaller than control 1), while sample 7 does not show any A2M at all. Moreover, sample 10 shows quite a good A2M score (bigger than the one for control 1 although smaller than control 2). Will sample 10, progress to metastatic melanoma while samples 9 and 7 will not? Finally, metastic melanona samples 5, 2 and 3 present A2M with scores smaller than sample 10 and control 2. Moreover among these metastatic samples, sample 2 (subcutaneous metastasis) is the one who presents a bigger A2M score. Will sample 2 progress for more far distant metastases? Will samples 5 and 3 end up their metastatic journey?
Methods
Proteomic analysis was performed at the Rockefeller University, Proteomics Center as described in Hamidi et al., 2017 (3). Only proteins with Mascot scores of approximately 90 or >90 were considered (4). The proteomic analysis excel files and each correspondent sample details were generously and kindly shared and donated by Dr. David Lyden, Weill Cornell Medical College, New York, USA. Original data files can be found at https://zenodo.org/record/6635906#.YqX5JnbMLIU
References:
1. https://gwyntwrscience.blogspot.com/2025/07/does-alpha-2-macroglobulin-2m-predicts.html
2. Zawieja et al.(2019).Lymphatic Cannulation for Lymph Sampling and Molecular Delivery. J Immunol; 203(8): 2339–2350
3. Hamidi et al. (2017) Identification of potential blood-derived extracellular vesicles biomarkers to diagnose and predict distant metastases in ER+ breast cancer patients, bioRxiv preprint doi: https://doi.org/10.1101/202291;
4. http://www.matrixscience.com/help/scoring_help.html
Comments
Post a Comment